Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15526387 | 0.90 | L3MBTL1 (0.43) | LMNADYRK1AFPR2SMN1; SMN2MAPK1 | |
| SCHEMBL15332887 | 0.85 | USP30 (0.51) | LMNADYRK1AFPR2PKMUSP2 | |
| SCHEMBL15333767 | 0.85 | USP30 (0.51) | LMNADYRK1AFPR2PKMUSP2 | |
| SCHEMBL15333523 | 0.85 | USP30 (0.51) | LMNADYRK1AFPR2PKMUSP2 | |
| SCHEMBL19689424 | 0.80 | USP30 (0.48) | LMNAFPR2SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL17678202 | 0.79 | CDK9 (0.51) | DYRK1AL3MBTL1KDM4EALDH1A1CCR5 | |
| SCHEMBL30847394 | 0.79 | CDK9 (0.51) | DYRK1AL3MBTL1KDM4EALDH1A1CCR5 | |
| SCHEMBL15333264 | 0.77 | USP30 (0.45) | FPR2CCR5 | |
| SCHEMBL2493364 | 0.77 | CDK9 (0.60) | LMNADYRK1AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL17586642 | 0.77 | CDK9 (0.56) | LMNADYRK1AMAPK1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | LMNA 3781/4885DYRK1A 4870/4885FPR2 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.